BioSpace News Archive

Drug Development

Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH

Hepagene Therapeutics, Inc today announced that it has screened the first patient in the USA for the RISE study, a Phase IIa clinical trial of HPG1860 in patients with non-alcoholic steatohepatitis (NASH ).

December 2, 2021
·
2 min read
Business

Qardio Names Mike Alvarez as President and Chief Executive Officer

Qardio, Inc. today announced the Company’s board of directors has appointed Mike Alvarez as President and Chief Executive Officer, effective immediately.

December 2, 2021
·
3 min read
Business

Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs

Venatorx Pharmaceuticals today announced that Scott McConnell, Pharm.D. has joined the Company as Vice President, Medical Affairs.

December 2, 2021
·
2 min read
Tarsier™ Pharma Announces two presentations at the International Ocular Inflammation Society (IOIS) 2021 Congress

Tarsier Pharma announced that the Company’s recent activities will be shared in two presentations at the International Ocular Inflammation Society (IOIS) Congress (on Dec. 2-5, 2021.)

December 2, 2021
·
3 min read
Pharm Country

Petros Pharmaceuticals Announces Closing of $10 Million Offering

Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, announced the closing of its previously announced registered direct offering and private placement with the company’s largest investor and other existing investors for gross proceeds of approximately 10.0 million.

December 2, 2021
·
4 min read
Pharm Country

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Tevogen Bio today announced TVGN-489, its lead investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTL) immunotherapy for treatment of COVID-19 in high-risk patients, is expected to retain activity against the B.1.1.529, or Omicron variant.

December 2, 2021
·
4 min read
Bonus BioGroup Reports 94% Survival Rate for Severe COVID-19 Cases in the Phase II Clinical Trial of its MesenCure Treatment

The positive results reported by the Company coincide with the emergence of the highly-mutated Omicron variant that has regalvanized the international community’s commitment to developing long-term solutions for the ongoing pandemic.

December 2, 2021
·
6 min read
Biocure Corporate Update and Financing

Development of it’s own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies in the near term.

December 2, 2021
·
5 min read
Hemodynamic Monitoring Devices Market Size to Reach Valuation of USD 1,566.7 Million in 2028 Growing at a CAGR of 6.1%, According to Latest Analysis by Emergen Research

The global hemodynamic monitoring devices market size is expected to reach USD 1,566.7 Million at a steady CAGR of 6.1% in 2028.

December 2, 2021
·
6 min read
Nerve Repair and Regeneration Market Size to Reach Valuation of USD 11.62 Billion by 2027 Growing at a CAGR of 9.0%, according to Emergen Research

The global Nerve Repair and Regeneration Market size will be worth USD 11.62 Billion by 2027, according to a current analysis by Emergen Research.

December 2, 2021
·
5 min read